ts-161
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 3, 2019 (NCT03919409)
Timeline
Indications
Mechanism of action
- Metabotropic glutamate receptor 3INHIBITOR
GRM3 inhibitor
- Metabotropic glutamate receptor 2INHIBITOR
GRM2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04821271 | Phase 2 | Jun 10, 2021 | National Institute of Mental Health (NIMH), Taisho Pharmaceutical |
| NCT03919409 | Phase 1 | Jun 3, 2019 | Taisho Pharmaceutical |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Taisho Pharmaceutical | For profit | 2 | 1 | 2 | 2019 |
| National Institute of Mental Health (NIMH) | Government | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1